DE102005002500A1 - Tetrahydrofuranderivate als Inhibitoren von Matrix-Metalloproteinasen - Google Patents

Tetrahydrofuranderivate als Inhibitoren von Matrix-Metalloproteinasen Download PDF

Info

Publication number
DE102005002500A1
DE102005002500A1 DE102005002500A DE102005002500A DE102005002500A1 DE 102005002500 A1 DE102005002500 A1 DE 102005002500A1 DE 102005002500 A DE102005002500 A DE 102005002500A DE 102005002500 A DE102005002500 A DE 102005002500A DE 102005002500 A1 DE102005002500 A1 DE 102005002500A1
Authority
DE
Germany
Prior art keywords
ring
het
defined above
alkyl
aryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
DE102005002500A
Other languages
German (de)
English (en)
Inventor
Manfred Dr. Schudok
Hans Dr. Matter
Armin Dr. Hofmeister
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Aventis France
Original Assignee
Sanofi Aventis Deutschland GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis Deutschland GmbH filed Critical Sanofi Aventis Deutschland GmbH
Priority to DE102005002500A priority Critical patent/DE102005002500A1/de
Priority to MX2007008427A priority patent/MX2007008427A/es
Priority to PCT/EP2006/000047 priority patent/WO2006077013A1/de
Priority to KR1020077016588A priority patent/KR101315788B1/ko
Priority to CN200680002746XA priority patent/CN101107252B/zh
Priority to CA2601357A priority patent/CA2601357C/en
Priority to EP20060700401 priority patent/EP1841772B1/de
Priority to BRPI0606493-0A priority patent/BRPI0606493A2/pt
Priority to JP2007551575A priority patent/JP4886704B2/ja
Priority to HK08103549.2A priority patent/HK1113367B/xx
Priority to AU2006207701A priority patent/AU2006207701B2/en
Publication of DE102005002500A1 publication Critical patent/DE102005002500A1/de
Priority to IL184527A priority patent/IL184527A/en
Priority to US11/777,324 priority patent/US8039481B2/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4355—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Communicable Diseases (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
DE102005002500A 2005-01-19 2005-01-19 Tetrahydrofuranderivate als Inhibitoren von Matrix-Metalloproteinasen Withdrawn DE102005002500A1 (de)

Priority Applications (13)

Application Number Priority Date Filing Date Title
DE102005002500A DE102005002500A1 (de) 2005-01-19 2005-01-19 Tetrahydrofuranderivate als Inhibitoren von Matrix-Metalloproteinasen
BRPI0606493-0A BRPI0606493A2 (pt) 2005-01-19 2006-01-05 derivados de tetrahidrofurano para uso como inibidores das metaloproteinases da matriz
JP2007551575A JP4886704B2 (ja) 2005-01-19 2006-01-05 マトリックスメタロプロテイナーゼ阻害剤として使用するためのテトラヒドロフラン誘導体
KR1020077016588A KR101315788B1 (ko) 2005-01-19 2006-01-05 매트릭스 메탈로프로테이나제의 억제제로서 사용하기 위한테트라하이드로푸란 유도체
CN200680002746XA CN101107252B (zh) 2005-01-19 2006-01-05 用作基质金属蛋白酶抑制剂的四氢呋喃衍生物
CA2601357A CA2601357C (en) 2005-01-19 2006-01-05 Tetrahydrofurane derivatives for use as inhibitors of matrix metalloproteinases
EP20060700401 EP1841772B1 (de) 2005-01-19 2006-01-05 Tetrahydrofuranderivate als inhibitoren von matrix-metalloproteinasen
MX2007008427A MX2007008427A (es) 2005-01-19 2006-01-05 Derivados de tetrahidrofurano para uso como inhibidores de metaloproteinasas de matriz.
PCT/EP2006/000047 WO2006077013A1 (de) 2005-01-19 2006-01-05 Tetrahydrofuranderivate als inhibitoren von matrix-metalloproteinasen
HK08103549.2A HK1113367B (en) 2005-01-19 2006-01-05 Tetrahydrofurane derivatives for use as inhibitors of matrix metalloproteinases
AU2006207701A AU2006207701B2 (en) 2005-01-19 2006-01-05 Tetrahydrofurane derivatives for use as inhibitors of matrix metalloproteinases
IL184527A IL184527A (en) 2005-01-19 2007-07-10 Tetrahydrofuran derivatives for use as matrix inhibitors of teloperotinase
US11/777,324 US8039481B2 (en) 2005-01-19 2007-07-13 Tetrahydrofuran derivatives for use as inhibitors of matrix metalloproteinases

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE102005002500A DE102005002500A1 (de) 2005-01-19 2005-01-19 Tetrahydrofuranderivate als Inhibitoren von Matrix-Metalloproteinasen

Publications (1)

Publication Number Publication Date
DE102005002500A1 true DE102005002500A1 (de) 2006-07-27

Family

ID=36124055

Family Applications (1)

Application Number Title Priority Date Filing Date
DE102005002500A Withdrawn DE102005002500A1 (de) 2005-01-19 2005-01-19 Tetrahydrofuranderivate als Inhibitoren von Matrix-Metalloproteinasen

Country Status (12)

Country Link
US (1) US8039481B2 (cg-RX-API-DMAC7.html)
EP (1) EP1841772B1 (cg-RX-API-DMAC7.html)
JP (1) JP4886704B2 (cg-RX-API-DMAC7.html)
KR (1) KR101315788B1 (cg-RX-API-DMAC7.html)
CN (1) CN101107252B (cg-RX-API-DMAC7.html)
AU (1) AU2006207701B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0606493A2 (cg-RX-API-DMAC7.html)
CA (1) CA2601357C (cg-RX-API-DMAC7.html)
DE (1) DE102005002500A1 (cg-RX-API-DMAC7.html)
IL (1) IL184527A (cg-RX-API-DMAC7.html)
MX (1) MX2007008427A (cg-RX-API-DMAC7.html)
WO (1) WO2006077013A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA014906B1 (ru) * 2005-12-01 2011-02-28 Элан Фармасьютикалз, Инк. 5-(арилсульфонил)пиразолопиперидины

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TR199800849T2 (xx) * 1995-11-13 1998-07-21 Hoechst Aktiengesellschaft Siklikle heterosiklik N-ikame edilmi� alfa-iminohidroksamla karbon asitleri
FR2748026B1 (fr) 1996-04-26 1998-06-05 Adir Nouveaux inhibiteurs de metalloproteases, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
US5868587A (en) * 1997-02-20 1999-02-09 The Whitaker Corporation Component mounting device
CA2297988A1 (en) * 1997-08-04 1999-02-11 Amgen Inc. Hydroxamic acid substituted fused heterocyclic metalloproteinase inhibitors
FR2795730B1 (fr) 1999-07-01 2001-08-31 Adir Nouveaux inhibiteurs de metalloproteases, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR2818643B1 (fr) * 2000-12-22 2003-02-07 Servier Lab Nouveaux inhibiteurs de metalloproteases, leur procede de preparation et les compositions pharmaceutiques que les contiennent
FR2825705B1 (fr) 2001-06-08 2005-05-20 Aventis Pharma Sa Nouveaux composes heterocycliques, leur preparation et leur utilisation comme medicaments, notamment comme anti-bacteriens
US6770647B2 (en) * 2001-08-17 2004-08-03 Bristol-Myers Squibb Pharma Company Bicyclic hydroxamates as inhibitors of matrix metalloproteinases and/or TNF-α converting enzyme (TACE)
DE10209299A1 (de) * 2002-03-02 2003-09-18 Aventis Pharma Gmbh Cyclische N-substituierte alpha-Iminocarbonsäuren zur selektiven Inhibierung von Kollagenase
CN1187332C (zh) * 2002-04-26 2005-02-02 中国科学院上海有机化学研究所 四氢异喹啉羟肟酸磺酰胺类化合物、合成方法及其用途
US7205315B2 (en) * 2003-09-27 2007-04-17 Sanofi-Aventis Deutschland Gmbh Bicyclic imino acid derivatives as inhibitors of matrix metalloproteinases
DE10344936A1 (de) * 2003-09-27 2005-04-21 Aventis Pharma Gmbh Bicyclische Iminosäurederivate als Inhibitoren von Matrix-Metalloproteinasen
DE102004031620A1 (de) * 2004-06-30 2006-02-02 Sanofi-Aventis Deutschland Gmbh 4-Trifluormethoxyphenoxybenzol-4`-sulfonsäuren, Verfahren zu ihrer Herstellung und Verwendung in Arzneimitteln

Also Published As

Publication number Publication date
AU2006207701A1 (en) 2006-07-27
US8039481B2 (en) 2011-10-18
WO2006077013A1 (de) 2006-07-27
US20080039489A1 (en) 2008-02-14
HK1113367A1 (en) 2008-10-03
CN101107252B (zh) 2010-12-01
IL184527A0 (en) 2007-10-31
KR101315788B1 (ko) 2013-10-14
CA2601357A1 (en) 2006-07-27
CA2601357C (en) 2013-09-10
EP1841772A1 (de) 2007-10-10
JP2008527013A (ja) 2008-07-24
CN101107252A (zh) 2008-01-16
EP1841772B1 (de) 2015-05-06
IL184527A (en) 2014-01-30
MX2007008427A (es) 2007-09-06
KR20070117541A (ko) 2007-12-12
BRPI0606493A2 (pt) 2009-06-30
JP4886704B2 (ja) 2012-02-29
AU2006207701B2 (en) 2011-09-15

Similar Documents

Publication Publication Date Title
EP2069289B1 (de) ISOSERINDERIVATE ALS INHIBITOREN DES KOAGULATIONSFAKTORS IXa
DE102004004974A1 (de) Thieno-Iminosäure-Derivate als Inhibitoren von Matrix-Metalloproteinasen
EP1560815B1 (de) Neue pyrimidin-4,6-dicarbons urediamide zur selektiven inhibierung von kollagenasen
EP2069288B1 (de) TARTRATDERIVATE ALS INHIBITOREN DES KOAGULATIONSFAKTORS IXa
EP1670766B1 (de) Bicyclische Iminosäurederivate zur Behandlung von (unter anderem) Erkrankungen des Bewegungsapparates
EP1587803A1 (de) Pyrimidin-4,6-dicarbonsäurediamide als selektive mmp 13 inhibitoren
EP1585728B1 (de) Iminosäurederivate als inhibitoren von matrix-metalloproteinasen
EP1763515B1 (de) 4-trifluormethoxyphenoxybenzol-4'-sulfonsäuren, verfahren zu ihrer herstellung und verwendung in arzneimitteln
EP1841772B1 (de) Tetrahydrofuranderivate als inhibitoren von matrix-metalloproteinasen
DE10251019A1 (de) Neue Pyrimidin-4,6-dicarbonsäurediamide zur selektiven Inhibierung von Kollagenasen
EP2054412B1 (de) Imino-imidazo-pyridinderivate mit antithrombotischer aktivität
DE10209299A1 (de) Cyclische N-substituierte alpha-Iminocarbonsäuren zur selektiven Inhibierung von Kollagenase
DE10254092A1 (de) Neue Pyrimidin-4,6-dicarbonsäurediamide zur selektiven Inhibierung von Kollagenasen
HK1113367B (en) Tetrahydrofurane derivatives for use as inhibitors of matrix metalloproteinases

Legal Events

Date Code Title Description
8127 New person/name/address of the applicant

Owner name: SANOFI-AVENTIS, PARIS, FR

R005 Application deemed withdrawn due to failure to request examination

Effective date: 20120120